Personalized immune cell therapy takes on lupus and MS
NCT ID NCT07361094
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new treatment for people with autoimmune diseases like lupus and multiple sclerosis that haven't responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and destroy the faulty cells causing the disease. The main goal is to check safety, but researchers will also look for signs of improvement over two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- autologous CD19-BCMA dual-target CAR T-cell therapy
- What this could lead to
- If this works, it could point toward a new treatment option for people with hard-to-treat autoimmune diseases, potentially reducing symptoms and flares.
- What could go wrong
- This is a very early Phase 1 trial with only 12 participants, so results may not apply to everyone. There are also risks of serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Boren Hospital
RECRUITINGBeijing, 100070, China